News
Press Releases
Aptar Pharma unveils eDevices, novel smart drug delivery devices for the future World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma will present its latest innovation, eDevices, at the Pharmapack Europe tradeshow, to be held in Paris, France, from February 15th to February 16th, 2012. READ MORE
Aptar pharma expands presence in India with a new manufacturing site near Mumbai Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, today announces the opening of a new facility near Mumbai, India. READ MORE
Aptar Pharma’s Oro-Mucosal Spray Device chosen for spasticity in multiple sclerosis Sativex® Oromucosal Spray, which uses an Aptar Pharma spray pump, is the first approved cannabis-based prescription medicine to be launched in Germany in the field of spasticity in multiple sclerosis management. World leader in nasal and pulmonary drug delivery devices, Aptar Pharma worked closely with GW Pharmaceuticals to develop the mouth spray device which allows Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)), a cannabinoid medicine, to be delivered to multiple sclerosis (MS) patients suffering from muscle spasticity. READ MORE
Aptar Pharma unveils DF30Plus, the New Optimized Metering Valve for HFA pMDIs World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma will unveil its latest innovation, DF30Plus, at the Drug Delivery to the Lungs (DDL) scientific conference, to be held in Edinburgh, Scotland, from December 7th to December 9th, 2011. This new DF30Plus metering valve is the result of continuous improvement to the already world leading DF30 technology platform. READ MORE
AptarGroup acquires minority interest in Oval Medical Technologies Crystal Lake, Illinois - AptarGroup, Inc. (NYSE: ATR) today announced that it has acquired a minority interest in Oval Medical Technologies Limited and has secured a license regarding certain of Oval Medical Technologies’ intellectual property. READ MORE
Aptar Pharma is conference partner for the 5th Symposium on Nasal and Pulmonary Drug Delivery Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, is conference partner for the Indian Pharmaceutical Association's fifth symposium on “Nasal and Pulmonary Drug Delivery” with the theme of “Regulatory Challenges: The Way Forward”. This symposium will be held in Mumbai, India, on November 10th and 11th, 2011. READ MORE
Resounding Success for Aptar Pharma's Scientific Roundtable on Pain Management Aptar Pharma, the world leading supplier of innovative non-invasive drug delivery devices recently organized a scientific roundtable on "Sprays for pain management as an alternative to injection and other routes of administration". This international scientific forum was held in Paris, France on October 4th 2011. READ MORE
Advances in Respiratory Innovation and Technology Symposium a huge sucess Building upon the growing success of previous events, Aptar Pharma, the world leading supplier of innovative non-invasive drug delivery devices, collaborated with event host SFDA (Chinese State Food and Drug Administration) training center, to organize the fourth symposium on Advances in Respiratory Innovation and Technology. This was held in Shanghai, China from September 21 to September 23, 2011. READ MORE
Aptar Pharma's nasal spray device chosen for pain management SPRIX® (Kétorolac Trométhamine), Nasal Spray, which uses an Aptar Pharma nasal spray pump, is the first non-opioid nasal spray to hit the U.S. market in the field of pain management. World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma worked closely with Roxro Pharma for over 7 years to develop the perfect nasal delivery system for SPRIX®. READ MORE
Record attendance at RDD Europe 2011 conference affirms continues strong interest in Pulmonary and Nasal Drug Delivery RDD® Europe 2011 in Berlin brought together pulmonary and nasal drug delivery experts from more than 30 countries for a unique exchange of knowledge, expertise, science and business networking. 465 delegates involved in pulmonary and nasal drug delivery attended the fourth RDD (Respiratory Drug Delivery) Europe conference in Germany last week. READ MORE
Aptar Pharma registers its contract test laboratories with the U.S. Food and Drug Administration Aptar Pharma’s French manufacturing sites in Le Vaudreuil and Val-de-Reuil have been registered as Contract Test Laboratories for extractables testing with the U.S. Food and Drug Administration (FDA). A number of pharmaceutical and biotechnology companies working with Aptar Pharma drug delivery devices... READ MORE
Pfeiffer and Valois announce the realignment of their pharmaceutical businesses under a common brand, Aptar Pharma, and unveil their new visual identities This market-focused realignment will make it even easier for customers to do business with Aptargroup through a wider and innovative range of products and services available under the new Aptar Pharma brand. READ MORE